Opportunities and challenges for antisense oligonucleotide therapies

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Antisense oligonucleotide (AON) therapies utilize short nucleotide strands to target RNA, modulating protein levels.
• Ten AON therapies are currently approved in the US and Europe, highlighting their therapeutic significance.
• Chemical modifications enhance AON stability, bioavailability, and RNA affinity, while delivery methods are crucial for efficacy.

Purpose of the Study:

• To provide a comprehensive overview of various antisense oligonucleotide (AON) therapeutic strategies.
• To focus on the application of AONs in treating inborn errors of metabolism.
• To discuss advancements in AON chemistry, delivery systems, and their impact on therapeutic outcomes.

Main Methods:

• Review of existing literature on antisense oligonucleotide (AON) therapies.
• Analysis of AON mechanisms, including RNA degradation (RNaseH, RISC) and translation inhibition.
• Examination of AON applications in modulating pre-mRNA splicing for protein restoration.

Main Results:

• AONs can effectively achieve protein knockdown through RNA degradation or translation inhibition.
• Single-stranded AONs are employed for protein restoration by modulating pre-mRNA splicing.
• AONs offer therapeutic potential for inherited metabolic diseases by intervening at the genetic level.

Conclusions:

• Antisense oligonucleotide (AON) therapies represent a versatile approach for genetic disorders.
• Advancements in AON chemistry and delivery are crucial for reducing side effects and improving patient outcomes.
• AONs hold significant promise for treating inborn errors of metabolism and other genetic conditions.